<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A (CsA) has been in clinical use for some decades, primarily for the prevention and treatment of organ transplant rejection and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In more recent years, <z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> has been recognized as beneficial in the treatment of <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatologic diseases</z:e>, such as: <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, <z:e sem="disease" ids="C0023646" disease_type="Disease or Syndrome" abbrv="">lichen planus</z:e>, <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e>, <z:hpo ids='HP_0001047'>atopic dermatitis</z:hpo>, <z:hpo ids='HP_0000999'>pyoderma</z:hpo> gangrenosum and <z:e sem="disease" ids="C0079293" disease_type="Disease or Syndrome" abbrv="">epidermolysis bullosa acquisita</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Above <z:hpo ids='HP_0000001'>all</z:hpo>, <z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> is an important therapeutic modality for several <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatologic diseases</z:e> that are refractory to other agents </plain></SENT>
</text></document>